Nedrow et al. investigated a CB-TE1K1P-chelated phosphoramidate inhibitor radiolabeled with copper-64, demonstrating high tumor uptake which correlated with PSMA expression, favorable pharmacokinetics, and excellent image contrast [79]. Here, FOLH1 is linked to neoplasm.